Vaccines save lives. Yet, despite concerted global efforts more than 1.5 million children die each year from vaccine preventable diseases. The Bill & Melinda Gates Foundation are at the center of this massive endeavor, and have enlisted labs around the world to help solve intractable problems in the developing world, including work recently published in Science Translational Medicine. The technology involves a microneedle patch that can administer a standard vaccine, painlessly, but also leave an invisible vaccination record right on the skin. Meaning those who need vaccines can get them, even in the most remote locations, and those who don’t need them, can prove they are protected without the need for paper or even digital records. You could carry the proof of prophylaxis with you, invisibly, as long as the vaccine protects you.

On this episode, we’ll meet two of the paper’s co-authors out of the Langer Lab at MITDr. Ana Jaklenec and Dr. Kevin McHugh.

For more information, read the publication: McHugh et al. 2019

This is the TomorrowScale Podcast. Hosted by Justin Briggs.

Listen on Your Favorite Podcast App

The TomorrowScale Podcast was created to showcase scientists and entrepreneurs who are building science-based businesses, and to hear their stories from the benches and in the trenches of research & development. The views expressed by the host and guests are their own, and the content of this show should not be considered legal, tax, or investing advice. Thanks to our guests for sharing their time and knowledge with us. Thank you for listening. Please science responsibly.

  • On this episode, our guest is economist Paul Kohlhaas, co-founder and CEO of Molecule and co-author of the VitaDAO whitepaper. We’ll head to Berlin, Germany, where Paul and his team of scientists, engineers, entrepreneurs and enthusiasts who are designing new ways to advance medicines. In Molecule’s case, they’re using tools not from the lab, but [...]

    Continue reading
  • The development of brain-machine or brain-computer interfaces (BCIs) approaches an […]

    Continue reading
  • At the center of every clinical trial is a group […]

    Continue reading
  • On this episode, our guest is economist Paul Kohlhaas, co-founder and CEO of Molecule and co-author of the VitaDAO whitepaper. We’ll head to Berlin, Germany, where Paul and his team of scientists, engineers, entrepreneurs and enthusiasts who are designing new ways to advance medicines. In Molecule’s case, they’re using tools not from the lab, but [...]

    Continue reading
  • The development of brain-machine or brain-computer interfaces (BCIs) approaches an […]

    Continue reading

Leave A Comment